Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically-important Gram-positive pathogen in both the hospital and outpatient settings. Over the past decade, the MRSA hospital market has become highly competitive due to the availability of numerous effective therapies. In the next few years, growth in this market will be further constrained by the anticipated generic entry of two key anti-MRSA agents: linezolid and daptomycin. Nevertheless, there remains commercial opportunity for new anti-MRSA agents able to address specific areas of unmet need.
This report focuses on the treatment of inpatients with MRSA infections and analyzes the hospital prescribing practices for infections due to MRSA and other clinically-important Gram-positive (GP) pathogens, such as community- and hospital-acquired MRSA, vancomycin-intermediate and -resistant S. aureus and vancomycin-resistant enterococci. Further, this study will evaluate the advantages and disadvantages of currently-available and emerging therapies to identify areas for product positioning and differentiation.

Questions Answered in This Report:

  • How are physicians treating serious infections due to MRSA and emerging and clinically-important GP pathogens?

  • How do physicians make treatment choices for MRSA and GP infec-tions, including empiric treatment for suspected MRSA infections and discharge therapies?

  • How are severe skin infections, blood stream infections, nosocomial pneumonia, intra-abdominal infections and bone and joint infections due to MRSA treated?

  • What are physicians’ therapy preferences and what factors and drug attributes influence current and future prescribing patterns? How re-ceptive are physicians to novel and emerging therapies?


Sample Frame & Methodology:

- 100 infectious diseases specialists completed a 45-minute online quanti-tative survey with several open-ended questions for qualitative feedback.

To qualify, respondents must meet the following criteria:

- Be board-certified in infectious diseases

- Treated a minimum of ten patients with MRSA within the last month

- Have been in practice a minimum of two years and a maximum of 30 years

- At east 50 percent of time practicing in the hospital setting

Key Drugs Covered:

- IV vancomycin, Zyvox (linezolid), Cu-bicin (daptomycin), Vibativ (telavancin), Teflaro (ceftaroline), Tygacil (tigecycline), clindamycin, trimethoprim/sulfomethaxozole, tedi-zolid, dalbavancin, oritavancin and BC-3781

Key Companies Mentioned:

- Bayer, Cubist, Durata, Forest, Nabriva, Pfizer, Roche, and The Medicines Company


- Final report in Powerpoint format

- Complete set of frequency tables, summary statistics, and cross tabulations can be provided upon request

- Proprietary question slide deck: Clients purchasing report prior to fielding will have the opportunity to include up to three proprietary questions

Related Reports:

- DecisionBase®: Gram-Negative Infections

- DecisionBase®: MRSA and Complicated Skin and Skin Structure Infec-tions

- Pharmacor®: Hospital-Treated Gram-Negative Infections

- Pharmacor®: Hospital-Treated Infections

- U.S. Physician and Payer Forum®: Gram-Negative Infections

- U.S. Physician and Payer Forum®: MRSA Infections

- Emerging Markets Physician and Payer Forum®: Hospital-Treated Infec-tions in China

- TreatmentTrends®:Hospital Discharge and Outpatient Trends (US)

- TreatmentTrends®: Gram-Negative Infections (EU)